Investigational drug · Phase 2
SAL-0951
Also called: SAL-0951 group
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Anemia.
Phase 2Last checked: Nov 20, 2026Latest source record: Dec 17, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "SAL-0951"
First trial start
2024
Sep 14, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SAL-0951", any sponsor or status.
Conditions studied
As listed on its trial records.
- Anemia
Approved drugs for the same conditions: Anemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "SAL-0951" as an intervention, largest first.
- SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney DiseasePivotal-lookingCompleted
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT06016036 · 156 participants · Start Dec 8, 2020 · Primary completion Oct 8, 2021
Drug: SAL-0951; Placebo · For: Renal Anemia in Non-dialysis Chronic Kidney Disease
Sites: Guangzhou, China
- Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance HemodialysisPivotal-lookingCompleted
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT06720025 · 100 participants · Start Sep 19, 2023 · Primary completion Jun 17, 2024
Drug: SAL-0951 tablets; rHuEPO injection · For: Anemia
Sites: Guangzhou, China
- SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid MalignanciesRecruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT06737081 · 60 participants (planned) · Start Sep 14, 2024 · Primary completion Dec 31, 2025
Drug: SAL-0951 tablets 4mg; SAL-0951 tablets 5mg · For: Anemia
Sites: Shanghai, China
- Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal DialysisPivotal-lookingCompleted
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT06720233 · 37 participants · Start Feb 22, 2002 · Primary completion Oct 18, 2024
Drug: SAL-0951 tablets · For: Anemia
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacokinetics, Pharmacodynamics, and Safety Evaluation of the Novel HIF-PH Inhibitor Enarodustat: An Open-Label Phase I Study in Healthy Chinese Participants.
Cui C, Niu X, Li H, et al. · Clin Drug Investig 2025
Also in development for Anemia
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- BCD-131pegdarbepoetin betaPhase 31 trial
Biocad · Anemia, Chronic Kidney Disease, Chronic Kidney Disease Patients on Hemodialysis
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
- OfirnoflastHT-6184Phase 22 trials
Halia Therapeutics, Inc. · Myelodysplastic Syndromes, Anemia, Myelodysplastic Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.